Molecular profile of oligodendrogliomas in young patients

Neuro-Oncology

Volumn 13, Issue 10, 2011, Pages 1099-1106

  Suri, Vaishali ^a   Jha, Prerana ^a   Agarwal, Shipra ^a   Pathak, Pankaj ^a   Sharma, Mehar Chand ^a   Sharma, Vikas ^a   Shukla, Sudhanshu ^b   Somasundaram, Kumaravel ^b   Mahapatra, Ashok Kumar ^a   Kale, Shashank Sharad ^a   Sarkar, Chitra ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

1p 19q; Adolescent; IDH1; MGMT; Oligodendrogliomas; P53; Pediatric; TP53; Young adults

Indexed keywords

ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MOLECULAR BIOLOGY; OLIGODENDROGLIOMA; PRESCHOOL CHILD; PROTEIN METHYLATION; SCHOOL CHILD;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MUTATION; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 80755159100     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor146     Document Type: Article

References (47)

1. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 1999;18:4144-4152. (Pubitemid 29363922)
2. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 1994;145:1175-1190. (Pubitemid 24345665)
3. Shukla B, Agarwal S, Suri V, et al. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurol. India. 2009;57:559-566.
4. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer. Inst. 1998;90:1473-1479. (Pubitemid 28482012)
5. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 2001;7:839-845. (Pubitemid 32708719)
6. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 2000;18:636-645. (Pubitemid 30078545)
7. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 2004;10:1871-1874. (Pubitemid 38375541)
8. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y. Correlation between promoter hypermethylation of the O6-methylguanine- deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery. 2004;54:349-357. (Pubitemid 38209403)
9. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer. 2005;113:379-385. (Pubitemid 40038704)
10. Dong SM, Pang JC, Poon WS, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol. Exp. Neurol. 2001;60:808-816. (Pubitemid 32678261)
11. Brandes AA, Tosoni A, Cavallo G, et al. ICNO. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J. Clin. Oncol. 2006;24:4746-4753. (Pubitemid 46630938)
12. Ishii D, Natsume A, Wakabayashi T, et al. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol. Med. Chir. (Tokyo). 2007;47:341-349. discussion 350. (Pubitemid 47328144)
13. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-1812.
14. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol. 2009;118:469-474.
15. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. 2010;12(1):83-91. [Epub ahead of print].
16. Sonoda Y, Kumabe T, Nakamura T, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009;100:1996-1998.
17. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009;360:765-773.
18. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11:341-347.
19. Gravendeel LA, Kloosterhof NK, Bralten LB, et al. Segregation of nonp. R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum. Mutat. 2010;31:E1186-199.
20. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res. 2009;15:6002-6007.
21. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol. 2009;27:5743-5750.
22. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 2010;16:1597-1604.
23. von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res. 1992;52:2987-2990.
24. Hagel C, Lacking G, Laas R, et al. Demonstration of p53 protein and TP53 gene mutation in oligodendrogliomas. Eur. J. Cancer. 1996;32:2242-2248.
25. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol Exp. Neurol. 2003;62:111-126. (Pubitemid 36176946)
26. Jeon YK, Park K, Park CK, Paek SH, Jung HW, Park S. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: A clinicopathological study using fluorescence in situ hybridization. Neuropathol. 2007;27:10-20. (Pubitemid 46146609)
27. Dohrmann GJ, Farwell JR, Flannery JT. Oligodendrogliomas in children. Surg. Neurol. 1978;10:21-25. (Pubitemid 8369661)
28. Razack N, Baumgartner J, Bruner J. Pediatric oligodendrogliomas. Pediatr. Neurosurg. 1998;28:121-129. (Pubitemid 28385582)
29. Raghavan R, Balani J, Perry A, et al. Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J. Neuropathol. Exp. Neurol. 2003;62:530-537. (Pubitemid 36560194)
30. Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol. 2005;109:387-392. (Pubitemid 40637311)
31. Kleihues P, Louis DN, Wiestler OD, Burger PC, Scheithauer BW. WHO grading of tumours of the central nervous system. In: Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee, WK, eds. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: IARC; 2007:10-11.
32. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007;28:622-629. (Pubitemid 46744292)
33. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch. Pathol. Lab. Med. 2007;131:242-251. Review.
34. Korshunov A, Sycheva R, Golanov A. Molecular stratification of diagnostically challenging high-grade gliomas composed of small cells: the utility of fluorescence in situ hybridization. Clin. Cancer Res. 2004;10:7820-7826. (Pubitemid 39587519)
35. Fuller CE, Schmidt RE, Roth KA, et al. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J. Neuropathol Exp. Neurol. 2003;62:1118-1128. (Pubitemid 37413823)
36. Myal Y, Del Bigio MR, Rhodes RH. Age-related differences in 1p and 19q deletions in oligodendrogliomas. BMC Clin. Pathol. 2003;3:6.
37. Hergersberg M, Mariani L, Vassella E, et al. Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors. J. Neurooncol. 2006;80:215-217. (Pubitemid 44614807)
38. Hyder DJ, Sung L, Pollack IF, et al. Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J. Neurooncol. 2007;83:1-8. (Pubitemid 46647158)
39. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000;343:1350-1354.
40. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 2009;27:5881-5886.
41. Jha P, Suri V, Jain A, et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery. 2010;67(6):1681-1691. Review.
42. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 2009;27:5874-5880.
43. Felsberg J, Wolter M, Seul H, et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010;119:501-507.
44. Jha P, Suri V, Singh G, et al. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn. Mol. Pathol. (In press).
45. Antonelli M, Buttarelli FR, Arcella A, et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol. 2010;99:209-215.
46. Jha P, Suri V, Sharma V, et al. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. Exp. Mol. pathol. 2011;91:385-393.
47. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 2009;174:1149-1153.